Plant Name: Zanthoxylum spinosum
Taxonomic Information:
Plant ID: NPO16614
Plant Latin Name: Zanthoxylum spinosum
Taxonomy Genus: Zanthoxylum
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
270788-2
Used in Medicines:
Unknown.
Geographical Distribution:
Jamaica
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| TSHR; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; AKR1B10; GFER; HSD17B10; ALDH1A1; POLB; | |
| ACHE; | |
| MAPK1; | |
| CA12; CA9; CA7; | |
| NR1H4; | |
| CASP1; CASP7; | |
| NFKB1; | |
| NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.630E-14 | 5.727E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.451E-12 | 3.758E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.839E-12 | 4.964E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.416E-11 | 1.603E-07 | AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, NR1H4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.098E-11 | 1.603E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.789E-11 | 2.392E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.015E-10 | 6.825E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.734E-09 | 2.092E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.399E-09 | 2.462E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.296E-09 | 6.948E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.090E-08 | 7.912E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.254E-08 | 8.809E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.068E-08 | 1.856E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 9.510E-08 | 5.051E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.251E-07 | 1.573E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.227E-06 | 5.565E-04 | CA12, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.026E-06 | 8.825E-04 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.074E-06 | 2.362E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.074E-06 | 2.362E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.074E-06 | 2.362E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.214E-05 | 4.479E-03 | PTPN1, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.812E-05 | 6.362E-03 | CASP7, MAPK1, NFKB1, NR1H4, PLA2G1B, TSHR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.886E-05 | 6.519E-03 | CA12, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.791E-10 | 3.073E-08 | CYP2C9, CYP2A6, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.279E-10 | 3.073E-08 | CYP2C9, PLA2G1B, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.778E-10 | 3.073E-08 | CYP2C9, CYP2A6, CYP2A13, CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.382E-09 | 4.700E-08 | CYP2C9, CYP2A6, CYP2A13, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.875E-08 | 7.821E-07 | CYP2C9, CYP2A6, CYP1A2, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 3.488E-06 | 6.776E-05 | CASP7, CASP1, MAPK1, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.078E-05 | 4.186E-04 | CYP2C9, CYP2A6, AKR1B10, PLA2G1B, CYP1A2, ALDH1A1, CYP2C19, CYP3A4, HSD17B10 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.720E-05 | 2.849E-04 | CYP2C9, CYP2D6, MAPK1, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 6.140E-05 | 7.591E-04 | CASP7, CASP1, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.794E-05 | 9.200E-04 | CYP2C9, PLA2G1B, CYP2C19 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 6.835E-05 | 7.747E-04 | CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.649E-06 | 3.738E-05 | CA12, CA7, CA9 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 4.798E-04 | 4.350E-03 | CASP7, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 2.327E-04 | 2.260E-03 | CASP1, MAPK1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 9.674E-04 | 8.223E-03 | CASP7, MAPK1, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.885E-05 | 2.849E-04 | CYP2A6, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDC25B; CA9; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
